Positive data on PTSD candidate propels Aptinyx

• Thinly traded micro cap Aptinyx (NASDAQ:APTX) jumps 49% after hours in reaction to positive results from a Phase 2 clinical trial evaluating NYX-783 in 153 patients with posttraumatic stress disorder (PTSD).
• NYX-783, an NMDA receptor modulator, showed statistically significant and clinically meaningful efficacy with a favorable safety profile.
• Participants receiving either 10 mg or 50 mg of NYX-783 once daily demonstrated statistically significant improvements in a PTSD scale called CAPS-5 compared to placebo.
• At week 4, 78% of subjects in the intent-to-treat population receiving 50 mg achieved a 30% improvement from baseline in CAPS-5 Total Score versus 44% in the control arm. 50% of this same group achieved a 50% improvement in CAPS-5 Total Score at week 4 compared to 26% in the placebo group.
• Management will host a conference call tomorrow, October 20, at 8:30 am ET to discuss the results.
• A pivotal study should launch in 2021.
• https://seekingalpha.com/news/3623450-positive-data-on-ptsd-candidate-propels-aptinyx-up-49